Reimbursement and coverage risk
Test demand depends on payer coverage; UnitedHealthcare's GeneSight change already hurt pharmacogenomics revenue.
- Scope
- Pharmacogenomics and other payer-sensitive tests
- Materiality
- high
Myriad Genetics, Inc
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier detection across oncology, prenatal health, and mental health. The company combines laboratory testing, clinical evidence development, and commercial services to embed genetic insights into routine care.
−40,4 %
69,9 %
−44,4 %
−1,6 %
2.49
2.26
| % | |
|---|---|
| Oncology testing | 55% Genetic and genomic tests for hereditary cancer risk, therapy selection, tumor profiling, and MRD. |
| Prenatal health | 25% Non-invasive prenatal screening and carrier screening products used in pregnancy care. |
| Mental health / pharmacogenomics | 15% GeneSight and related tests that help guide medication selection and dosing. |
| Biopharma services and other | 5% Companion diagnostic development, biomarker services, and other precision medicine offerings. |
Myriad sells primarily to healthcare providers, including community physicians, specialists, and large health systems...
- Community medicine providersprimary
Physicians and clinics that order Myriad's tests for routine patient care because the company has broad commercial reach and EMR integration goals.
- Oncology specialists and cancer centersprimary
Oncologists and cancer care teams buying hereditary cancer, HRD, tumor profiling, and MRD-related tests to guide treatment and surveillance.
- Prenatal care providersprimary
OB/GYNs and maternal-fetal medicine practices ordering prenatal screening and carrier screening products for pregnancy risk assessment.
- Mental health prescriberssecondary
Psychiatrists and other prescribers using GeneSight to help select medications and improve treatment response.
- Biopharma companiessecondary
Drug developers buying biomarker, companion diagnostic, and regulatory support services for clinical programs.
Myriad is headquartered in the United States and generates most of its business there, with active sales operations in...
- •United States is the core market for testing volume and reimbursement
- •Japan is an active international sales market
- •Certain products are distributed through international partners
- •European EndoPredict was divested, reducing non-U.S. exposure
- •Single-lab processing model increases operational concentration risk
Myriad's strategy is to accelerate profitable growth by deepening its position in cancer care, expanding prenatal...
01
Grow oncology across the Cancer Care Continuummedium-term
Oncology is the largest strategic opportunity and supports cross-selling across hereditary cancer, therapy selection, and MRD.
02
Scale prenatal and mental health franchisesshort-term
These businesses provide recurring demand and can offset pressure in pharmacogenomics reimbursement.
03
Improve operating leverage and profitabilitymedium-term
Automation and standardized processes are intended to lower cost per test and reduce operating expenses as a share of revenue.
Myriad faces reimbursement pressure, especially in pharmacogenomics, where UnitedHealthcare coverage changes have...
Cybersecurity and data privacy risk
The company handles sensitive genetic and health data, so breaches could cause financial, regulatory, and reputational damage.
- Scope
- IT systems, cloud services, patient data
- Materiality
- high
Single-laboratory operational concentration
Each test is processed in one laboratory facility, so an outage or compliance issue could seriously harm operations.
- Scope
- All test lines
- Materiality
- high
Third-party specimen collection dependency
Some tests rely on external labs and phlebotomy clinics; loss of access could prevent testing and delay revenue.
- Scope
- Prequel and other collection-dependent tests
- Materiality
- medium
Competitive and technological disruption
The diagnostics market has frequent product launches, price competition, and changing standards that can pressure share and margins.
- Scope
- Oncology, prenatal, and mental health testing
- Materiality
- medium
Revenue recognition for diagnostic tests
Can create quarter-to-quarter volatility in reported sales
Goodwill and intangible asset impairment
Can materially reduce earnings and book value
Valuation allowance on deferred tax assets
Affects tax expense and effective tax rate
Cost of revenue and lab efficiency
Impacts gross margin and operating leverage
: 28/04/2026